Overview

Original Research

BIOSIMILARS IN OPHTHALMOLOGY: A REVIEW

JAWAHAR LAL GOYAL 1, PREETI BHARDWAJ 2, HOLMES NAOREM 3, and PULKIT GANDHI 4.

Vol 18, No 11 ( 2023 )   |  DOI: 10.5281/zenodo.10153134   |   Author Affiliation: Professor and Head of Ophthalmology, SMS&R, Sharda University, Greater Noida, U.P 1; Junior Resident, Department of Ophthalmology, SMS&R, Sharda University, Greater Noida, U.P 2; Senior Resident, Department of Ophthalmology, SMS&R, Sharda University, Greater Noida, U.P 3; Assistant Professor, Department of Internal Medicine/ Nephrology, Lake Erie College of Osteopathic Medicine, Rochester, NY 4.   |   Licensing: CC 4.0   |   Pg no: 332-342   |   Published on: 18-11-2023

Abstract

There has been a parallel advancement in the field of biosimilars with other recent biologic medications like cell line science and protein expression science. These are molecules that are chemically similar to their already approved biological medication counterparts which enable a faster and more cost-effective production as they only require one clinical trial, unlike the reference product which has to usually undergo two. Recently, various biosimilars for ophthalmic use have been developed and studied in various parts of the world. Razumab, a biosimilar to Ranibizumab approved in India in 2015, has been extensively studied in clinical trials which has shown its effectiveness and safety in various chorioretinal vascular diseases. The future of the field of biosimilars is expected to be shaped by several factors like healthcare policies, increased market penetration, and competition. Hence, further studies and research need to be conducted in this lucrative field of biosimilars.

Keywords

Biosimilars, Ophthalmology, Razumab